Examining IGFBP7 as a potential therapeutic target in people with ALS.

Abstract excerpt

A single nucleotide variant in an insulin-like growth factor (IGFBP7) promotor, which reduces IGFBP7 levels in brain, was previously associated with an ALS "reversal" phenotype. This raises the question of whether IGFBP7 might be a therapeutic target in ALS. Here, we use a combinatorial analysis to show that IGFBP7-Antisense (AS1) is associated with resistance to ALS. In ALS patients' blood, we demonstrate...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Aged
• Share to Amyotrophic Lateral Sclerosis
• Share to Insulin-Like Growth Factor Binding Proteins